- Home
- NAD vs NRIX Comparison
NAD vs NRIX Comparison
Compare NAD & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAD | NRIX |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NAD | NRIX |
|---|---|---|
| Price | $10.49 | $15.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 1.3M | ★ 3.6M |
| Earning Date | 01-01-0001 | 10-12-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.26 |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | $786.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.04 |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $9.66 | $12.23 |
| 52 Week High | $12.31 | $28.23 |
Technical Indicators
Market Signals| Indicator | NAD | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 26.96 |
| Support Level | $9.75 | $14.65 |
| Resistance Level | $11.95 | $17.47 |
| Average True Range (ATR) | 0.22 | 1.32 |
| MACD | 0.00 | -0.98 |
| Stochastic Oscillator | 18.86 | 6.81 |
Price Performance
Historical ComparisonAbout NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.